Ged Giblin
Corporate Officer/Principal bei Convergence Pharmaceuticals Ltd.
Profil
Ged Giblin is currently the Head-Chemistry & Preclinical Development at Convergence Pharmaceuticals Ltd.
He previously worked as the Head-Medicinal Chemistry at GlaxoSmithKline (Pharmaceutical Operations).
Aktive Positionen von Ged Giblin
| Unternehmen | Position | Beginn |
|---|---|---|
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | 06.10.2010 |
Ehemalige bekannte Positionen von Ged Giblin
| Unternehmen | Position | Ende |
|---|---|---|
| GlaxoSmithKline (Pharmaceutical Operations) | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
| GlaxoSmithKline (Pharmaceutical Operations) |
